Background and objectives Renal function is an important predictor of survival in cirrhosis and liver transplantation. GFR estimates using serum cystatin C (CysC) are proposed as better predictors of renal function than ones on the basis of serum creatinine (Cr). Our aims were: (1) evaluate correlations between serum CysC and different methods of creatinine measurements; (2) compare CysC and Cr GFR formulas with 51 Cr-EDTA; and (3) evaluate liver-related parameters potentially influencing GFR.
Introduction
Renal dysfunction is a well established predictor of increased mortality in both acute liver failure and cirrhosis, particularly after the development of complications, such as sepsis (1) , and after liver transplantation (2) . Serum creatinine (Cr) is only an indirect marker of renal function, i.e., of GFR. Measurement of Cr suffers from a variety of interferences and is not standardized (3, 4) . We and others previously reported (4, 5) that different methods used for measuring Cr give significantly different values. Recently we found a lack of agreement in creatinine values (6) between different laboratories that used the same method of measurement. We also reported (7) that Cr values significantly overestimate renal function in women. Other factors affecting Cr are also known (8) . Thus the most frequently used GFR formulas (8) , the Cockcroft-Gault (C-G) (9) and Modification of Diet in Renal Disease (MDRD) (10) , use several corrections for age, gender, ethnicity, and body weight. Different creatinine-based formulas were evaluated (11) in 1447 patients with cirrhosis, all transplant candidates, using 125 I-iothalamate clearance as a reference standard; the four-, five-, and six-variable MDRD equations were similar and had greater accuracy than the C-G formula, but the concordance with 125 I-iothalamate clearance was lower than the equivalent MDRD estimations in other populations.
Inulin clearance and other direct methods using injected exogenous radiolabeled substances ( 51 Cr-EDTA, 125 I-iothalamate, and 99m Tc-DTPA) are the most accurate to assess renal function. The 51 Cr-EDTA method is an accepted substitute of the "gold standard" inulin clearance (12) .
Serum cystatin C (CysC) is a low molecular weight protein functioning as an extracellular inhibitor of cysteine proteases (13) . CysC is freely filtered by the renal glomeruli and subsequently metabolized in the proximal tubules. Given these features and the reported independence of CysC from age, gender, and body composition (14) , it has been considered a more sensitive indicator of renal function compared with Cr in several disease groups (15) including cirrhosis (16 -18) .
Thus several CysC-based GFR equations have been derived (19) , all in nonliver disease patients. Despite being more accurate than Cr-based formulas (15), they still lacked significant correlation with direct methods of GFR estimation. To date only one study evaluated (20) CysC GFR, using the Larsson et al. (21) and Hoek et al. (22) formulas in patients with cirrhosis, comparing them with MDRD (10) and C-G (9). Inulin clearance was the gold standard. The CysC formulas were more accurate than the Cr formulas but had significantly different values of GFR in comparison with inulin clearance.
In cirrhosis, CysC has been proposed as a marker of liver disease stage (23). Significant differences were found in CysC values but not Cr values between ChildPugh class A, B, and C patients (18) . Cr and CysC concentrations correlated well with the severity of liver disease in 180 patients (24) , but a gold standard to assess renal function was not used. Increased CysC values in cirrhosis may be related to increased production, secondary to active inflammatory and fibrotic processes (25) , decreased renal function, or both.
Our aims were: (1) to assess correlations between serum CysC and different Cr measurement methods and to evaluate whether bilirubin (Bil) concentration affects CysC; (2) to compare "true" GFR using a gold standard method and estimated GFR (eGFR) using Cr and CysC; and (3) to investigate whether a new formula to estimate GFR in cirrhosis using parameters related to liver function could be derived.
Materials and Methods
We used 256 consecutive blood samples obtained during routine clinical care from 65 patients with cirrhosis, at the Royal Free Hospital, being part of a previously reported cohort (4) and samples from a separate cohort of 74 patients, with cirrhosis candidates for liver transplantation who had 51 Cr-EDTA GFR measurement (C 51 Cr-EDTA) as pretransplant assessment. We compared C 51 Cr-EDTA with Cr and CysC-GFR formulas. In the 74 transplant candidates, stepwise multivariate linear regression analysis was used to identify any liver disease-specific factors influencing renal function to derive a new GFR model. We tested bilirubin interference with CysC with dilution/titration curves in blood samples taken from five patients with a median bilirubin of 582 mol/L (range, 303 to 639 mol/L).
Clinical, hematologic, and biochemical data were collected on the day of the C 51 Cr-EDTA. The ChildPugh (CPT) (26) 
Analyses in the First Cohort
For serum creatinine measurement we evaluated four commonly used methods in the UK and the USA (27) : (1) O'Leary modified Jaffe (mJCr): potassium ferricyanide was used to oxidize bilirubin to biliverdin (prestep), and an increase in absorbance was measured at 505 nm and blanking at 570 nm; (2) compensated (rate blanked) kinetic Jaffe (cJCr): measured increase in absorbance at 505 nm with blanking at 570 nm; (3) enzymatic creatinine (ECr): we used a creatininase/creatinase/sarcosine oxidase system with detection at 546 nm and absorbance blanking at 700 nm, and a Roche Modular P unit (Roche Diagnostics, Ltd., Lewes, UK) was used for all three assays, calibrated using a lyophilized human serum-based Cfas calibrator (Roche Diagnostics) standardized using the isotope dilution mass spectrometry method; and (4) CysC was analyzed by immunonephelometry using a BN-ProSpec analyzer (Dade Behring BNProSpec). The manufacturer's reference interval for healthy subjects is 0.53 to 0.95 mg/L. Assay sensitivity was 0.005 mg/L; intra-assay and interassay coefficients of variation were 2% and 3.6%, respectively.
Analyses in the Second Cohort
The cJCr and ECr methods when bilirubin Ͼ171 mol/L were used to measure serum creatinine, and the same methodology was used to measure CysC.
The C
51
Cr-EDTA was performed by sampling blood after intravenous injection of tracer at 2, 4, and 6 hours. GFR was calculated using the slope-intercept technique, correcting for body surface area, and the fast exponential curve recommended by the British Nuclear Medicine Society guidelines (28) .
Cr-based GFR was calculated using the four variable MDRD formulas, which are considered the best in adults (12, 29) and in cirrhosis (11, 20) formed. Parametric data were compared using unpaired t tests and ANOVA tests and nonparametric data by the Mann-Whitney's and Kruskal-Wallis tests. For parametric post tests pairwise subgroup comparison a Student-Newman-Keul's test was used, and the Bonferroni correction was used for nonparametric comparisons. Nonparametric correlations were evaluated by Spearman, and parametric ones were evaluated by Pearson correlation. The chi-square test and Fischer's exact test (when the total number of observations was Ͻ20) were used as qualitative tests.
Bland and Altman analysis (30) and the concordance correlation coefficient (31) were used to evaluate agreement. Significance testing was two-sided and set to Ͻ0.05.
Results

Comparison of Serum Cystatin C with Different Serum Creatinine Measurements
There were 65 patients with cirrhosis (60% male) with 254 blood samples ( Table 1) Table 1) . Correlations between CysC and the four Cr measurements methods were reasonable being 0.72, 0.71, 0.72, and 0.72, respectively, for JCr, cJCr, ECr, and mJCr (all P Ͻ 0.001).
Relationship of Serum Bilirubin to Serum Cystatin C
The groups were subdivided according to bilirubin values: (1) Bil Ͻ100 mol/L (n ϭ 60, 23.6%); (2) between 100 and 199 mol/L (n ϭ 89, 35%); (3) between 200 and 399 mol/L (n ϭ 57, 22.4%); or (4) Ͼ400 mol/L (n ϭ 48, 18.9%). The median values for mJCr, cJCr, ECr, JCr, and CysC according to bilirubin concentrations are shown in Table 2 . Comparisons of CysC median values between the Bil Ͼ400 group and every other group were significant (P Ͻ 0.0001 for Bil Ͻ100; P Ͻ 0.0001 for Bil Ն100 and Ͻ200; and P Ͻ 0.04 for Ն200 and Ͻ400).
The correlation between CysC and bilirubin was poor (r ϭ 0.42, P Ͻ 0.001). Dilution/titration analysis showed that serum CysC concentration was not influenced by bilirubinemia with values as high as 639 mol/L. The poor correlation of CysC with bilirubin and a much stronger one with Cr indicate that the increase seen with CysC as bilirubin increased is mostly influenced by renal function and not by liver disease. As we previously reported, correlations between the four different creatinine and bilirubin measurements were poor (4) being 0.56, 0.42, 0.38, and 0.44, respectively, for mJCr, cJCr, ECr, and JCr (all P Ͻ 0.0001).
Evaluation of 51 Cr-EDTA GFR in Cirrhosis and Comparison with MDRD and Cystatin C GFR Formulas
In the 74 patients with cirrhosis, the mean MELD score was 12 Ϯ 5.5, range 2 to 25, and the mean CPT score was 8.2 Ϯ 2.4, range 5 to 14 (Child A/B/C, 22/27/25). Liver disease etiology was: alcohol, 12; viral hepatitis (B/C), 28; cryptogenic/nonalcoholic- Table 3 ). The median creatinine and cystatin C values differed significantly, both being increased in the group with GFR Ͻ70 ml/min per 1.73 m 2 (P Ͻ 0.0001). The liver-related variables that were significantly different between these groups were encephalopathy, which was worse, and lower levels of both transaminases, in the GFR group Ͻ70 ml/min per 1.73 m 2 . The 74 patients were also subdivided according to CPT stage (A/B/C); without significant differences for Cr, CysC, or GFR measured by 51 Cr-EDTA, MDRD, Larsson, and Hoek ( Cr-EDTA and MDRD was moderately good (r ϭ 0.72; 95% CI, 0.59 to 0.81; P Ͻ 0.0001), whereas between Cr-EDTA GFR were better in those without ascites than with ascites, being 0.76 versus 0.52 (P ϭ NS), 0.75 versus 0.31 (P ϭ 0.0001), and 0.72 versus 0.28 (P ϭ 0.0002), respectively. The correlations for Cr did not differ significantly in the two groups, for neither the single values nor the estimated GFR values using the MDRD formula. The latter findings suggest that ascites may significantly influence the estimated GFR when the CysC formulas are used but not the Cr formula.
Degree of Agreement between Different Formulas for GFR in Cirrhosis
The differences between true GFR and eGFRs were significantly different (F ϭ 3.38, P ϭ 0.01) (Figure 1) . In a pairwise comparison, differences between Cr-EDTA and Hoek (P Ͼ 0.05). Bland-Altman plots (Figure 2) showed that the most accurate method was Hoek, and the most precise method was MDRD. However, both methods overestimated GFR in comparison with 51 Cr-EDTA especially for values Ͻ70 ml/min per 1.73 m 2 , and thus neither CysC GFR formula had good accuracy.
Multivariate Analyses and Evaluation of Improved Accuracy of Modified GFR Formulas
We performed a stepwise multivariate linear regression analysis of liver parameters in two analyses using Cr-EDTA, the factors used in stepwise order were: age, gender, CPT score, albumin, bilirubin, ascites, encephalopathy, international normalized ratio, platelets, aspartate aminotransferase, alanine aminotransferase, C-reactive protein, and the presence of HCC. Partial correlations and relative P values are shown in Table 5 .
Independently associated factors were included in GFR estimation: GFR (ml/min per 1.73 m 
Evaluation of New Derived GFR Formulas in Cirrhosis
Using the Bland-Altman analysis, the two new formulas were more accurate compared with the MDRD, Larsson, and Hoek formulas. The new Cr-eGFR was more precise than the new CysC-eGFR ( Figure 2 ). We further evaluated the accuracy of the new eGFR formulas using a method proposed by the National Kidney Foundation (8) that measures the percentage of GFR estimates that fall within 10, 30, and 50% above or below the measured GFR (P10, P30, and P50, respectively). The new Cr-eGFR formula was the most accurate (Table 6 ). When the same evaluations were performed in the subgroup of patients with the true GFR of less than 70 ml/min per 1.73 m 2 , P10, P30 and P50 were 15, 48, and 70% for the new Cr-eGFR; 15, 44, and 66% for the new CysC-eGFR; 23, 42, and 53% for Hoek; and 15, 46, and 73% for MDRD.
Discussion
We used two cohorts of patients with cirrhosis. In the first cohort we assessed correlations of serum CysC with different measurement methods for Cr and whether worsening liver function expressed by increasing bilirubin concentrations affected its values. In the second cohort we assessed whether CysC and its derived GFR equations performed better in comparison with Cr and its derived GFR equations, compared with 51 Cr-EDTA GFR.
Bil correlated poorly with CysC in both cohorts, whereas CysC was strongly correlated with Cr. Similar to our results, initial studies assessing the interference of Bil with CysC measurement showed that results were not influenced by hyperbilirubinaemia up to 700 mol/L (33). There were no significant differences across the CPT stage, at variance with a previous report of only 25 patients (18) .
Both CysC formulas significantly overestimated renal clearance compared with C 51 Cr-EDTA. Multivariate severity of the CPT score added accuracy to a Cr-based GFR formula and the presence of ascites to a CysCbased formula. Interestingly it also showed that female gender is still an important factor affecting the Cr-based formula (7) but not the CysC-based formula. The new Cr formula resulted the best in comparison with C 51 Cr-EDTA rather than MDRD, Hoek, and the new CysC formulas.
The four-variable MDRD formula is derived from large patient cohorts without liver disease (8) but has only been validated in one large cohort of patients with cirrhosis (11) . The CysC equations have also been derived from nonliver disease populations (93 patients with diabetes, vasculitis, and glomerulopathies (22) and 100 patients of unspecified cause [21] ) and only evaluated in 44 patients with cirrhosis (20) . In our patients with cirrhosis, the Hoek CysC formula performed better than the Larsson, having less bias, and was better than the MDRD. However, the MDRD was more precise than both the Hoek and Larsson formulas. Nevertheless, each formula overestimated renal clearance significantly in comparison with C 51 Cr-EDTA. There is only one published study similar to ours (20) , evaluating retrospectively 44 patients with cirrhosis, comparing CysC-based (Larsson and Hoek) and Cr-based (MDRD and C-G) formulas with inulin clearance as the gold standard. The median CPT score was similar, but with a lower median Bil (29 mol/L) but higher mean Cr (94.5 mol/L) and mean CysC (1.21 mg/dl). All eGFR formulas overestimated the true GFR significantly. CysC-based formulas performed similarly, and both were more precise than Cr-based formulas. However, accuracies measured with the relative P10, P30, and P50 were surprisingly very low; for the best P10 it was 2.3%, for the best P30 it was 13.6%, and for the best P50 it was 20.5%. These differences are greater than in our cohort and than in patients with chronic kidney disease, in whom the MDRD formula was validated; the P30 accuracy was 92%, and the P50 accuracy was 98% (8) . The accuracy of MDRD in our cohort with cirrhosis was 64% and 81%, similar to the reference study (8) . For our new Cr eGFR formulas, the accuracy was 78 and 89%, although the accuracy was reduced in the subgroup with a true GFR Ͻ70 ml/min per 1.73 m 2 , in which the P10, P30, and P50 were 15, 48, and 70%, respectively, for the new Cr eGFR and 15, 44, and 66%, respectively, for the new CysC eGFR, with 23, 42, and 53%, respectively, for Hoek, and 15, 46, and 73%, respectively, for MDRD. This clearly demonstrates that in cirrhosis the relative accuracies for estimating GFR drop with decreasing renal function. Although these values are far better than the very low values reported by Poge et al. (20) , our new formulas cannot be used in clinical practice but demonstrate that parameters of liver function improve standard formulas and need validation in large cohorts. Gonwa et al. (11) reported a P30 accuracy of 67% for the four-factor MDRD, a finding very similar to our result of 64%, which was in a much smaller cohort. This suggests that our cohort is a representative one for cirrhosis. In patients with chronic kidney disease even with a very low GFR (Ͻ30 ml/min per 1.73 m 2 ), P30 and P50 were much better at 69 and 88%, respectively, for each of the four-, five-, and six-variable MDRD formulas (34) , showing that patients with cirrhosis are a special case when GFR is low.
A limitation of this study was that the method used as the gold standard for measuring GFR has not been extensively validated in patients with ascites. However, we used the three-sample method to measure Cr-EDTA clearance, which is more accurate than the one-sample method.
Conclusions
This study shows that serum CysC does not provide a sufficient improvement over serum Cr in reflecting renal function in patients with cirrhosis, using the most widely used formulas to estimate GFR. A new GFR formula for Cr improved accuracy in estimating GFR by including the CPT score (i.e. an index of liver dysfunction) as well as female gender.
Because existing CysC-eGFRs do not reflect true GFR with great accuracy in cirrhosis and because even the new formulas of eGFR that we derived, although better than existing formulas, still did not have a good correlation with a direct method of GFR measurement, more studies are required to elucidate the usefulness of CysC as a marker of GFR and to develop accurate eGFR formulas. In cirrhosis there needs to be good evidence that CysC has significant advantages over Cr to recommend the use of CysC. This is particularly so when the GFR falls below Ͻ70 ml/min per 1.73 m 2 , which is known to have an adverse effect on prognosis both before (1, 35, 36) and after (2,37) liver transplantation.
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